Grigorios Siokas Acquires 349,825 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas purchased 349,825 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was bought at an average cost of $0.20 per share, with a total value of $69,965.00. Following the completion of the transaction, the chief executive officer directly owned 14,597,917 shares in the company, valued at $2,919,583.40. The trade was a 2.46% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, July 29th, Grigorios Siokas acquired 766,284 shares of Cosmos Health stock. The shares were bought at an average price of $0.18 per share, for a total transaction of $137,931.12.
• On Thursday, June 11th, Grigorios Siokas acquired 218,447 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.21 per share, for a total transaction of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas acquired 701,447 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.23 per share, for a total transaction of $161,332.81.

Cosmos Health Stock Performance

NASDAQ COSM opened at $0.22 on Friday. Cosmos Health Inc. has a 1 year low of $0.16 and a 1 year high of $1.32. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.08 and a quick ratio of 0.92. The firm has a market cap of $12.94 million, a price-to-earnings ratio of -0.34 and a beta of 4.83. The company has a fifty day moving average price of $0.23 and a 200-day moving average price of $0.33.

Cosmos Health (NASDAQ:COSM) last announced its earnings results on Wednesday, May 20th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. The company had revenue of $18.40 million during the quarter, compared to the consensus estimate of $17.93 million. As a group, equities research analysts predict that Cosmos Health Inc. will post 0.01 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cosmos Health has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of COSM. Renaissance Technologies LLC grew its stake in Cosmos Health by 16.7% in the 1st quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock valued at $124,000 after purchasing an additional 55,925 shares during the period. XTX Topco Ltd raised its stake in shares of Cosmos Health by 52.1% during the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock worth $50,000 after purchasing an additional 34,117 shares during the period. Finally, Citadel Advisors LLC raised its stake in shares of Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares during the period. Institutional investors own 12.61% of the company’s stock.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.